Literature DB >> 29999596

Nasal high-frequency oscillatory ventilation and CO2 removal: A randomized controlled crossover trial.

Roberto Bottino1, Federica Pontiggia1, Cinzia Ricci2, Alessandro Gambacorta2, Angela Paladini2, Vladimiras Chijenas3, Arunas Liubsys4, Jurate Navikiene4, Ausrine Pliauckiene4, Domenica Mercadante5, Mariarosa Colnaghi5, Milena Tana2, Chiara Tirone2, Alessandra Lio2, Claudia Aurilia2, Roberta Pastorino6, Velia Purcaro2, Gianfranco Maffei7, Pio Liberatore7, Chiara Consigli8, Cristina Haass8, Gianluca Lista9, Massimo Agosti10, Fabio Mosca5, Giovanni Vento2.   

Abstract

OBJECTIVE: To compare short-term application of nasal high-frequency oscillatory ventilation (nHFOV) with nasal continuous positive airway pressure (nCPAP). WORKING HYPOTHESIS: nHFOV improves CO2 removal with respect to nCPAP in preterm infants needing noninvasive respiratory support and persistent oxygen supply after the first 72 h of life. STUDY
DESIGN: Multicenter non-blinded prospective randomized crossover study. PATIENT SELECTION: Thirty premature infants from eight tertiary neonatal intensive care units, of mean ± SD 26.4 ± 1.8 weeks of gestational age and 921 ± 177 g of birth weight.
METHODOLOGY: Infants were randomly allocated in a 1:1 ratio to receive a starting treatment mode of either nCPAP or nHFOV delivered by the ventilator CNO (Medin, Germany), using short binasal prongs of appropriate size. A crossover design with four 1-h treatment periods was used, such that each infant received both treatments twice. The primary outcome was the mean transcutaneous partial pressure of CO2 (TcCO2 ) value during the 2-h cumulative period of nHFOV compared with the 2-h cumulative period of nCPAP.
RESULTS: Significantly lower TcCO2 values were observed during nHFOV compared with nCPAP: 47.5 ± 7.6 versus 49.9 ± 7.2 mmHg, respectively, P = 0.0007. A different TcCO2 behavior was found according to the random sequence: in patients starting on nCPAP, TcCO2 significantly decreased from 50.0 ± 8.0 to 46.6 ± 7.5 mmHg during nHFOV (P = 0.001). In patients starting on nHFOV, TcCO2 slightly increased from 48.5 ± 7.8 to 49.9 ± 6.7 mmHg during nCPAP (P = 0.13).
CONCLUSIONS: nHFOV delivered through nasal prongs is more effective than nCPAP in improving the elimination of CO2 .
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  nasal continuous positive airway pressure; nasal high-frequency oscillatory ventilation; preterm infants

Mesh:

Substances:

Year:  2018        PMID: 29999596     DOI: 10.1002/ppul.24120

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  5 in total

1.  Noninvasive high-frequency oscillatory ventilation versus bi-level positive pressure ventilation in premature infants with respiratory failure: A retrospective study.

Authors:  Wenqian Chen; Zhiqing Chen; Shuhua Lai; Wenhong Cai; Yunfeng Lin
Journal:  Pak J Med Sci       Date:  2022 May-Jun       Impact factor: 2.340

2.  Eligibility Criteria and Representativeness of Randomized Clinical Trials That Include Infants Born Extremely Premature: A Systematic Review.

Authors:  Leeann R Pavlek; Brian K Rivera; Charles V Smith; Joanie Randle; Cory Hanlon; Kristi Small; Edward F Bell; Matthew A Rysavy; Sara Conroy; Carl H Backes
Journal:  J Pediatr       Date:  2021-04-21       Impact factor: 6.314

Review 3.  Non-invasive Respiratory Support of the Premature Neonate: From Physics to Bench to Practice.

Authors:  Ibrahim Sammour; Sreenivas Karnati
Journal:  Front Pediatr       Date:  2020-05-08       Impact factor: 3.418

4.  Nasal HFOV versus nasal IPPV as a post-extubation respiratory support in preterm infants-a randomised controlled trial.

Authors:  Soutrik Seth; Bijan Saha; Anindya Kumar Saha; Suchandra Mukherjee; Avijit Hazra
Journal:  Eur J Pediatr       Date:  2021-04-23       Impact factor: 3.183

5.  Non-invasive High-Frequency Oscillatory Ventilation as Initial Respiratory Support for Preterm Infants With Respiratory Distress Syndrome.

Authors:  Shu-Hua Lai; Ying-Ling Xie; Zhi-Qing Chen; Rong Chen; Wen-Hong Cai; Luo-Cheng Wu; Yun-Feng Lin; Yi-Rong Zheng
Journal:  Front Pediatr       Date:  2022-01-11       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.